To clarify the value of combined use of bio-markers for the diagnosis of advanced stage gallbladder cancer and to observe the associated hepato-haematological abnormality. Serum level of MDA, CEA and CA19.9 were measured in 51 patients with gallbladder cancer (GBC), and 21 healthy controls using TBARs method for MDA and chemiluminescent microparticle immunoassay (CMIA) for CEA & CA19.9. In these patients LFT was estimated by the help of a commercial kit (APL, SGOT, SGPT, Total bilirubin, direct bilirubin, Total protein, Albumin & Globulin kit, Coral clinical systems, Goa, India) and haematological parameters were measured by standard procedure using Cell Counter (Medonic M-Series) which is used in Mahavir Cancer Institute, Patna, India. Serum MDA, CEA and CA19.9 levels in the GBC group were significantly higher when compared with those in healthy control groups (P < 0.05). With a single tumor marker for GBC diagnosis, the sensitivity of MDA was the highest (95.23%), with the highest specificity being in CEA (98.7%). Diagnostic accuracy was highest with a combination of MDA, CEA & CA19.9 (72.54%). Hepatohaematological parameters has been found to be significant differences of the mean ± SE of MDA, CEA, CA19.9, RBC, WBC, haemoglobin, ALP, SGOT, SGPT, Total bilirubin, Direct bilirubin & Globulin between the GBC and the normal groups (P < 0.05). There was no significant differences of the PLT, Total protein & Albumin between the GBC and normal groups (P >0.05). The combined detection of these markers may prove to be useful for diagnosis of GBC, assessing therapeutic effects, and predicting a prognosis. A majority of patients had an abnormal hepato-haematoparameters at the time of diagnosis requiring meaningful palliative treatment.
